The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-κB pathway

Pharmazie

Volumn 67, Issue 2, 2012, Pages 187-192

  Wang, Huihan ^a   Wang, Xiaobin ^a   Li, Yingchun ^a   Liao, Aijun ^a   Fu, Beibei ^a   Pan, Hongyu ^a   Liu, Zhuogang ^a   Yang, Wei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA ACTIN; BORTEZOMIB; DAUNORUBICIN; GLYCOPROTEIN P; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; TRANSCRIPTION FACTOR RELA; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; COLORING AGENT; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PROTEASOME; PYRAZINE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CELL NUCLEUS; CELL STRAIN K 562; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; BIOSYNTHESIS; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL SURVIVAL; COLORING AGENTS; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; I-KAPPA B PROTEINS; INDICATORS AND REAGENTS; K562 CELLS; NF-KAPPA B; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION FACTOR RELA;

EID: 84860622188     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1585     Document Type: Article

References (32)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622.
2. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR (2005) Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23: 5943-5949.
3. Barlogie B Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J (2004) Treatment of multiple myeloma. Blood 103: 20-32.
4. Bentires-Alj M Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97.
5. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24: 937-944.
6. Bold RJ, Virudachalam S, McConkey DJ (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100: 11-17.
7. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29 Suppl 1: 21-31.
8. Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, Ishibe Y, Ogasawara Y, Doihara H, Shimizu N (2005) Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 117: 670-682.
9. Gil L, Styczynski J, Dytfeld D, Debski R, Kazmierczak M, Kolodziej B, Rafinska B, Kubicka M, Nowicki A, Komarnicki M, Wysocki M (2007) Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res 27: 4021-4025.
10. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
11. Lee CH, Jeon YT, Kim SH, Song YS (2007) NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29: 19-35.
12. Lei HY, Zhao XL (2007) [Clinical significance of NF-kappaB continual activity and expression of WT1 and MDR1 in acute nonlymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15: 253-257.
13. Leonard GD, Polgar O, Bates SE (2002) ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3: 1652-1659.
14. Li Y, Yuan H, Yang K, Xu W, Tang W, Li X (2010) The structure and functions of P-glycoprotein. Curr Med Chem 17: 786-800.
15. Liao ZJ, Ma WL, Meng W, Liang S, Meng FY, Zheng WL (2008) [Effect of Velcade on the gene expression profiles of K562 cells: study of its molecular mechanism]. Nan Fang Yi Ke Da Xue Xue Bao 28: 373-376.
16. Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794-1807.
17. Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA (2007) A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59: 207-215.
18. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144.
19. McCloskey SM, McMullin MF, Walker B, Irvine AE (2008) The therapeutic potential of the proteasome in leukaemia. Hematol Oncol 26: 73-81.
20. Messermith WA, Baker SD, Lassiter L, Sullivan RA, Dinh K, Almuete VI, Wright JJ, Donehower RC, Carducci MA, Armstrong DK (2006) Phase I trial of bortezomib incombination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12: 1270-1275.
21. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377-2380.
22. Ohashi K (2008) [Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma]. Gan To Kagaku Ryoho 35: 1029-1032.
23. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105: 3058-3065.
24. Richardson PG., Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57: 33-47.
25. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC Jr. (2006) A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107: 2688-2697.
26. Singh G, Alqawi O, Espiritut M (2010) Metronomic PDT and cell death pathways. Methods Mol Biol 635: 65-78.
27. Terpos E, Roussou M, Dimopoulos MA (2008) Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol 4: 639-654.
28. Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, Giaccone G (2007) A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 13: 3642-3651.
29. Wang H, Liu X, Xu B (2008) [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16: 531-537.
30. Yamamura M, Hirai T, Yamaguchi Y (2010) [Proteasome inhibitor.] Nippon Rinsho 68: 1079-1084.
31. Yang HH, Ma MH, Vescio RA, Berenson JR (2003) Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 21: 4239-4247.
32. Zineldeen DH, Uranishi H, Okamoto T (2010) NF-kappa B signature on the aging wall. Curr Drug Metab 11: 266-275.